Osteoporosis: Epidemiology Forecast to 2027
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person’s bone cells dissolve (resorption) and new bone cells grow back (formation). The bones become so weak and brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture.
To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market research. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.
In the 7MM, the total prevalent cases of osteoporosis will increase from 45,617,583 cases in 2017 to 52,482,628 cases in 2027, at an Annual Growth Rate (AGR) of 1.50%. In the 7MM, the diagnosed prevalent cases of osteoporosis will increase from 21,637,066 cases in 2017 to 24,553,120 cases in 2027, at an AGR of 1.35%. GlobalData forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of osteoporosis during the forecast period.
Scope
The Osteoporosis Epidemiology Report and Model provide an overview of the risk factors and global trends of osteoporosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
This report ncludes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of osteoporosis, and total and diagnosed prevalent cases of primary osteoporosis, segmented by sex and age in these markets. In addition, this report provides a 10-year epidemiological forecast for the total and diagnosed prevalent cases of secondary osteoporosis, total and diagnosed prevalent cases of osteopenia, segmented by sex. The report also includes the total and diagnosed prevalent cases of type 1 (postmenopausal) osteoporosis, and the total and diagnosed prevalent cases of type 2 (age-associated/ senile) osteoporosis, and total and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use.
The osteoporosis epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The Osteoporosis Epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global osteoporosis market.
Quantify patient populations in the global osteoporosis market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for osteoporosis therapeutics in each of the markets covered.
Understand magnitude of osteoporosis types in each market.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.